NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease

Go back to NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
NAMSCO Corporation (NASDAQ: NAMS) Delayed: 21.58 +0.32 (1.51%)
Previous Close $21.26    52 Week High $0.00 
Open $21.25    52 Week Low $0.00 
Day High $21.79    P/E N/A 
Day Low $21.02    EPS $0.00 
Volume 1,265,985